Status
Conditions
Treatments
About
IBIS is a prospective, observational study, which aims to assess the cost of CDI per day, hospitalization and year including description of incremental costs in hospitalized patients, and recurrent episodes, in German hospitals. Exposure to CDI drugs will not be influenced and remains at the discretion of the treating physician.
In addition to treatment, Health-related quality of life (HRQL) will be analyzed using standardized questionnaires.
Full description
Documentation of patient is performed by using the web-based survey platform www.ClinicalSurveys.net which was set up by researchers of the University Hospital of Cologne. This survey platform enables an optimal performance in epidemiological, observational, and interventional trials and is characterized by layered access security and frequent data backup. It has been used for numerous registry and cohort studies with approval of competent authorities and ethics boards.
The following two differences of data documentation are observed:
Retrospective data documentation:
Data of patients that are too sick to provide informed consent, (up to 30% of all patients enrolled) will be obtained retrospectively, at least 90 days after diagnosis and will be documented in an anonymized fashion. For these patients, documentation of HRQL will not be feasible.
Prospective data documentation:
Data of patients with an informed consent.
The following data items are retrospectively or prospectively documented into our database, depending on if a informed consent exists or not:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Index episode of CDI based on
Ongoing or new hospitalization at inclusion into the study.
Written informed consent (IC) has been obtained from the study subject or a legal representative.
Exclusion criteria
541 participants in 1 patient group
Loading...
Central trial contact
Maria Vehreschild, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal